Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study

Fig. 1

Shows the frequency of various types of clinical relevance of cholelithiasis in the study groups. Out of 308 patients included in the study, cholelithiasis was detected in 96 patients. Asymptomatic cholelithiasis was encountered in 38 patients; 14, 8, 4, and 12 patients with dulaglutide, semaglutide, liraglutide, and non-GLP1-RAs users, respectively. Symptomatic uncomplicated cholelithiasis was noticed in 26 patients; 9, 8, 4, and 5 in liraglutide, semaglutide, dulaglutide, and non-GLP1RAs users, respectively. Symptomatic complicated cholelithiasis was reported in 32 patients; 9, 9, 7, and 7 in liraglutide, semaglutide, dulaglutide, and non-GLP1RAs users, respectively

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us